Claudia Milanaccio

Claudia Milanaccio

Auto-generated profile, based on publicly available information

Claudia Milanaccio

Neuro-oncology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MGMaria Luisa Garrè
Maria Luisa Garrè
ACArmando Cama
Armando Cama
FBFrancesca Bagnasco
Francesca Bagnasco
GMGiovanni Morana
Giovanni Morana
FGFelice Giangaspero
Felice Giangaspero
TPTorsten Pietsch
Torsten Pietsch
Purpose: We aimed to test the hypothesis that medulloblastoma (MB) variants show a different age distribution and clinical behavior reflecting their specific biology, and that MB occurring at very young age is associated with cancer predisposition syndromes such as Gorlin syndrome (GS). Experimental Design: We investigated the frequency, age distribution, location, response to treatment, outcome, and association with familial cancer predisposition syndromes in a series of 82 cases of MB in patients ages <14 years diagnosed at the Giannina Gaslini Children's Hospital, Genoa, between 1987 and 2004. Results: Desmoplastic MB and MB with extensive nodularity (MBEN), were present in 22 of 82 cases (27%) and were more frequent in children ages ≤3 years (13 of 25; 52%). In this age group, MBEN was significantly more frequent than desmoplastic MB and classic MB (P < 0.001) and had a good prognosis. MBEN was associated with GS in 5 of 12 cases. Overall, 8 cases occurred in the context of familial tumor predisposition syndromes (5 GS, 1 each NF1, Li-Fraumeni, and Fragile X) and 7 of these patients were ages ≤3 years at diagnosis. Desmoplastic histology and a more intensive treatment represented independent favorable prognostic factors in multivariate analysis (P = 0.003 and P = 0.0139, respectively). Metastasis was a predictor of bad outcome (P = 0.0001). Conclusions: Our data indicate that biologically different MB entities warrant risk-adapted treatment and that MBEN is strongly associated with GS. Patients, ages ≤3 years, with MB and their families should be investigated for tumor predisposition syndromes such as GS.

1 January 1997 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GTG P Tonini
G P Tonini
LBL Boni
L Boni
Andrea PESSIONAndrea PESSION
Andrea PESSION
DRD Rogers
D Rogers
AIA Iolascon
A Iolascon
BBB De Bernardi
B De Bernardi
PURPOSE: To evaluate the prognostic role of MYCN oncogene amplification in children with neuroblastoma. PATIENTS AND METHODS: Of 694 children (age, 0 to 15 years) with previously untreated neuroblastoma, 295 (42%) were evaluated at diagnosis for MYCN gene amplification. RESULTS: Clinical characteristics and survival results of 295 patients studied and 399 not studied for MYCN were comparable. In 48 of 295 patients studied for MYCN (16%), the gene was amplified (> or = three gene copies). Amplification was more frequent in children older than 1 year, with abdominal tumor (18% v 7%), advanced disease, normal vanillylmandelic (VMA) urinary excretion, and high lactate dehydrogenase (LDH), ferritin, and neuron-specific enolase (NSE) serum levels. In patients studied for MYCN, the 5-year overall survival (OS) rate was higher for children aged less than 1 year (90% v 44%), with extraabdominal tumor, stage 1 or 2 versus 3 versus 4, and normal NSE, LDH, and ferritin serum levels. Patients with amplified MYCN had a worse OS (odds ratio [OR], 3.38; confidence interval [CI], 2.22 to 5.16). This association held after adjustment for other characteristics. The impact of MYCN amplification was greater in patients with favorable characteristics, in particular age (OR, 10.28 for infants; 2.08 for older children) and stage (OR, 35.3 for stage 1 to 2; 8.41 for stage 3; 1.76 for stage 4). However, of 29 children with stage 4s, all three with amplified MYCN survive. In a multivariate analysis, the prognostic role of MYCN amplification, age, and stage was confirmed, but the size of the effect of MYCN was dependent on age and stage. CONCLUSION: MYCN amplification is associated with a worse prognosis in children with neuroblastoma at all ages and stages except 4s. This association is most pronounced in children with otherwise favorable prognostic indicators, and in these children should be considered as an indication for more intensive intervention.

26 November 1999 in British Journal of Cancer
Verified
Journal Article
Open access
AGAlberto Garaventa
Alberto Garaventa
OBO Bellagamba
O Bellagamba
MPM S Lo Piccolo
M S Lo Piccolo
CMC Milanaccio
C Milanaccio
ELE Lanino
E Lanino
BBB De Bernardi
B De Bernardi
Incomplete response to therapy may compromise the outcome of children with advanced neuroblastoma. In an attempt to improve tumour response we incorporated 131I-metaiodobenzylguanidine (131I-MIBG) in the treatment regimens of selected stage 3 and stage 4 patients. Between 1986 and 1997, 43 neuroblastoma patients older than 1 year at diagnosis, 13 with stage 3 (group A) and 30 with stage 4 disease (group B) who had completed the first-line protocol without achieving complete response entered in this study. 131I-MIBG dose/course ranged from 2.5 to 5.5 Gbq (median, 3.7). The number of courses ranged from 1 to 5 (median 3) depending on the tumour response and toxicity. The most common acute side-effect was thrombocytopenia. Later side-effects included severe interstitial pneumonia in one patient, acute myeloid leukaemia in two, reduced thyroid reserve in 21. Complete response was documented in one stage 4 patient, partial response in 12 (two stage 3, 10 stage 4), mixed or no response in 25 (ten stage 3, 15 stage 4) and disease progression in five (one stage 3, four stage 4) Twenty-four patients (12/13 stage 3, 12/30 stage 4) are alive at 22-153 months (median, 59) from diagnosis. 131I-MIBG therapy may increase the cure rate of stage 3 and improve the response of stage 4 neuroblastoma patients with residual disease after first-line therapy. A larger number of patients should be treated to confirm these results but logistic problems hamper prospective and coordinated studies. Long-term toxicity can be severe.

13 February 2006 in Cancer
Verified
Journal Article
Closed access
PDF file
MCMassimo Conte
Massimo Conte
SPStefano Parodi
Stefano Parodi
BBBruno De Bernardi
Bruno De Bernardi
CMClaudia Milanaccio
Claudia Milanaccio
KMkatia mazzocco
katia mazzocco
RHRiccardo Haupt
Riccardo Haupt

27 April 2019 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
Arnoldo PiccardoArnoldo Piccardo
Arnoldo Piccardo
DTDomenico Tortora
Domenico Tortora
SMSamantha Mascelli
Samantha Mascelli
MSMariasavina Severino
Mariasavina Severino
GPGianluca Piatelli
Gianluca Piatelli
GMGiovanni Morana
Giovanni Morana

23 September 2015 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
GMGiovanni Morana
Giovanni Morana
Arnoldo PiccardoArnoldo Piccardo
Arnoldo Piccardo
MPMatteo Puntoni
Matteo Puntoni
PNPaolo Nozza
Paolo Nozza
ACArmando Cama
Armando Cama
ARAndrea Rossi
Andrea Rossi
Background 1H-MR spectroscopy (MRS) and 18F-dihydroxyphenylalanine (DOPA) PET are noninvasive imaging techniques able to assess metabolic features of brain tumors. The aim of this study was to compare diagnostic and prognostic information gathered by 18F-DOPA PET and 1H-MRS in children with supratentorial infiltrative gliomas or nonneoplastic brain lesions suspected to be gliomas. Methods We retrospectively analyzed 27 pediatric patients with supratentorial infiltrative brain lesions on conventional MRI (21 gliomas and 6 nonneoplastic lesions) who underwent 18F-DOPA PET and 1H-MRS within 2 weeks of each other. 1H-MRS data (choline/N-acetylaspartate, choline-to-creatine ratios, and presence of lactate) and 18F-DOPA uptake parameters (lesion-to-normal tissue and lesion-to-striatum ratios) were compared and correlated with histology, WHO tumor grade, and patient outcome. Results 1H-MRS and 18F-DOPA PET data were positively correlated. Sensitivity, specificity, and accuracy in distinguishing gliomas from nonneoplastic lesions were 95%, 83%, and 93% for 1H-MRS and 76%, 83%, and 78% for 18F-DOPA PET, respectively. No statistically significant differences were found between the 2 techniques (P > .05). Significant differences regarding 18F-DOPA uptake and 1H-MRS ratios were found between low-grade and high-grade gliomas (P≤.001 and P≤.04, respectively). On multivariate analysis, 18F-DOPA uptake independently correlated with progression-free survival (P≤.05) and overall survival (P = .04), whereas 1H-MRS did not show significant association with outcome. Conclusions 1H-MRS and 18F-DOPA PET provide useful complementary information for evaluating the metabolism of pediatric brain lesions. 1H-MRS represents the method of first choice for differentiating brain gliomas from nonneoplastic lesions.18F-DOPA uptake better discriminates low-grade from high-grade gliomas and is an independent predictor of outcome.